Litcius/Paper detail

Structure-Based Discovery of Proline-Derived Arginase Inhibitors with Improved Oral Bioavailability for Immuno-Oncology

Min Lu, Hongjun Zhang, Derun Li, Matthew C. Childers, Qinglin Pu, R.L. Palte, Symon Gathiaka, Thomas W. Lyons, Anandan Palani, Peter W. Fan, Peter Spacciapoli, J. Richard Miller, Hyelim Cho, Mangeng Cheng, Kalyan Chakravarthy, Jennifer O’Neil, Padmanabhan Eangoor, Adam Beard, Hai‐Young Kim, Josep Saurí, Hakan Günaydin, David L. Sloman, Phieng Siliphaivanh, Jared N. Cumming, Christian Fischer

2021ACS Medicinal Chemistry Letters26 citationsDOIOpen Access PDF

Abstract

was well tolerated following multiple days of dosing at concentrations that exceed those required for serum arginase inhibition and concomitant arginine elevation in a syngeneic mouse carcinoma model.

Topics & Concepts

ArginaseBioavailabilityDosingPharmacologyDrugConcomitantChemistryDrug discoveryPotencyMedicineArginineIn vitroBiochemistryAmino acidInternal medicineClick Chemistry and ApplicationsChemical Synthesis and AnalysisAdenosine and Purinergic Signaling
Structure-Based Discovery of Proline-Derived Arginase Inhibitors with Improved Oral Bioavailability for Immuno-Oncology | Litcius